CAJ | 학술논문

目的：研究Beclin-1在肾癌中的表达及其临床意义。方法通过免疫组化检测肾癌中自噬相关基因 Beclin-1的表达情况，初步探讨 Beclin-1在肾癌组织中表达情况。并分析 Beclin-1表达与肾癌复发及生存时间的相关性；多因素分析探讨其是否为肾癌预后的独立危险因素。结果对133例肾癌及12癌旁组织进行检测，肾癌组织中Beclin-1基因表达水平明显低于癌旁组织（P<0.05）。Beclin-1基因阴性肾癌患者的复发率明显高于Beclin-1基因阳性患者（P=0.041）；Beclin-1阳性肾癌患者总体生存率明显高于Beclin-1阴性肾癌患者（P=0.008）。多因素分析显示，Beclin-1，肿瘤分级、分期及淋巴结转移与否是肾癌复发、死亡的独立预后因素。结论 Beclin-1低表达是肾癌预后不良的独立危险因素，它可能成为肾癌个体化治疗的潜在靶点。
목적：연구Beclin-1재신암중적표체급기림상의의。방법통과면역조화검측신암중자서상관기인 Beclin-1적표체정황，초보탐토 Beclin-1재신암조직중표체정황。병분석 Beclin-1표체여신암복발급생존시간적상관성；다인소분석탐토기시부위신암예후적독립위험인소。결과대133례신암급12암방조직진행검측，신암조직중Beclin-1기인표체수평명현저우암방조직（P<0.05）。Beclin-1기인음성신암환자적복발솔명현고우Beclin-1기인양성환자（P=0.041）；Beclin-1양성신암환자총체생존솔명현고우Beclin-1음성신암환자（P=0.008）。다인소분석현시，Beclin-1，종류분급、분기급림파결전이여부시신암복발、사망적독립예후인소。결론 Beclin-1저표체시신암예후불량적독립위험인소，타가능성위신암개체화치료적잠재파점。
Objective To investigate the clinical significance of Beclin- 1 in renal cell carcinoma patients. Methods Immunohistochemical was employed to detect Beclin-1 expression level in renal cell carcinoma. To preliminarily assess the correlation between Beclin-1 and clinical pathological features in renal cell carcinoma. Furthermore, prognostic roles (recurrence, metastasis and survival) of Beclin-1 as a single agent index in renal cancer were analyzed using Kaplan-Meier survival curve. Finally, multi-variable analysis was conducted to explore whether Beclin-1 is independent prognostic risk factor for renal cancer. Results In 133 cases of renal cell carcinoma and 12 normal adjacent tissues, Beclin-1 gene expression levels and protein were significantly lower than the adjacent normal renal tissue (P<0.05). The recurrence rate of Beclin-1 positive renal cancer patients was significantly lower than those with Beclin-1 negative (P=0.041). Overall survival rate of Beclin- 1 positive renal carcinoma patients was significantly higher than Beclin-1 negative patients (P=0.008). In addition, multivariate analysis showed that Beclin-1, tumor grade, tumor stage and lymph node status were independent prognostic factors of recurrence and death for renal cell carcinoma. Conclusion Beclin-1 low expression is an independent risk factor for poor prognosis of renal cancer. We can conclude that Beclin-1 may become a potential therapy target of renal carcinoma for individualized treatment.